Bidar, Frank
Monneret, Guillaume
Berthier, Franck
Lukaszewicz, Anne-Claire
Venet, Fabienne
Funding for this research was provided by:
Hospices Civils de Lyon
Article History
Received: 17 May 2022
Accepted: 21 May 2022
First Online: 8 June 2022
Declarations
:
: This project was part of an ongoing prospective observational clinical study (RICO, REA-IMMUNO-COVID). It was approved by ethics committee (Comité de Protection des Personnes Ile de France 1—N°IRB/IORG #: IORG0009918) under Agreement Number 2020-A01079-30. This clinical study was registered at ClinicalTrials.gov (NCT04392401). The committee waived the need for written informed consent because the study was observational, with a low risk to patients, and no specific procedure, other than routine blood sampling, was required. Oral information and non-opposition to inclusion in the study were mandatory and were systematically obtained before any blood sample was drawn. This was recorded in patients’ clinical files. If a patient was unable to consent directly, non-opposition was obtained from the patient’s legally authorized representative and reconfirmed from the patient at the earliest opportunity.
: Not applicable.
: FBe is bioMérieux’s employee. This private company had no role in the study design, result analysis and decision to publish this study. All other authors have declared no conflicts of interest.